Medical devices

David P. White, M.D. Appointed Senior Vice President of Medical Affairs at Apnimed

Tuesday, July 27, 2021 - 12:30pm

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that David P. White, M.D., a world-renowned leader in sleep disorders has been appointed Senior Vice President of Medical Affairs.

Key Points: 
  • Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that David P. White, M.D., a world-renowned leader in sleep disorders has been appointed Senior Vice President of Medical Affairs.
  • Clinicians understand that obstructive sleep apnea is a prevalent and debilitating medical condition affecting the health and well-being of patients.
  • There is a tremendous unmet need for a safe, effective, and easy-to-use treatment option that addresses the underlying cause of the disease.
  • In addition to his new position at Apnimed, Dr. White is a Professor of Medicine, part-time, at Harvard Medical School in Boston, Mass.

First VR Radiology Platform Approved By Health Canada for Diagnostic Work

Tuesday, July 27, 2021 - 11:00am

Luxsonic, a Canadian company and pioneer in immersive medicine, is pleased to announce that SieVRt, an all-in-one Virtual Reality (VR) radiology suite has been approved by Health Canada as a Class 2 Medical Device for use in diagnostic radiology.

Key Points: 
  • Luxsonic, a Canadian company and pioneer in immersive medicine, is pleased to announce that SieVRt, an all-in-one Virtual Reality (VR) radiology suite has been approved by Health Canada as a Class 2 Medical Device for use in diagnostic radiology.
  • It is the first time that a VR software platform of this kind has been approved as a Class 2 Medical Device by a national regulatory agency.
  • Now that Health Canada has approved SieVRt, radiologists will be able to bring their own personalized virtual office with them wherever they go.
  • Now that the Diagnostic module has been approved, it will be launched in Canada later this year.

Cardiovascular Systems, Inc. to Attend Three Investor Conferences in August

Tuesday, July 27, 2021 - 12:00pm

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.

Key Points: 
  • Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.
  • The companys orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.
  • For additional information, please visit www.csi360.com and connect on Twitter @csi360.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005130/en/

MicroPort® Cardiac Rhythm Management Business Announces US$150 Million Series C Investment

Tuesday, July 27, 2021 - 8:49am

SHANGHAI, July 27, 2021 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort") announced that MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which is MicroPort's subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million.

Key Points: 
  • SHANGHAI, July 27, 2021 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort") announced that MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which is MicroPort's subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million.
  • Hillhouse Capital Group and MicroPort will co-lead the Series C investment and will invest US$20 million and US$47 million, respectively.
  • After the completion of this transaction, MicroPort will continue to be the majority shareholder of MicroPort CRM.
  • Through its long-standing expertise in CRM, MicroPort CRM develops, manufactures and markets around the world cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure.

TA Associates Announces Strategic Growth Investment in Elos Medtech

Tuesday, July 27, 2021 - 6:30am

TA Associates, a leading global growth private equity firm, today announced it has completed a majority growth investment in Elos Medtech AB (NASDAQ STOCKHOLM: ELOS B), a leading innovative full-service contract development and manufacturing organization (CDMO) in the global medical device market.

Key Points: 
  • TA Associates, a leading global growth private equity firm, today announced it has completed a majority growth investment in Elos Medtech AB (NASDAQ STOCKHOLM: ELOS B), a leading innovative full-service contract development and manufacturing organization (CDMO) in the global medical device market.
  • We have followed Elos Medtech for several years and have been highly impressed by the company and its management team, said Lovisa Lander, a Principal at TA.
  • We look forward to working with the Elos Medtech team to solidify its position as a global, high-quality development and manufacturing partner with a MedTech focus.
  • I am very pleased to welcome TA as the majority shareholder of Elos Medtech, said Jan Wahlstrm, CEO of Elos Medtech.

Pulse Biosciences Schedules Second Quarter 2021 Financial Results Conference Call for August 9, 2021

Monday, July 26, 2021 - 9:05pm

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, announced today it will report financial results for the second quarter of 2021 after market close on Monday, August 9, 2021.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, announced today it will report financial results for the second quarter of 2021 after market close on Monday, August 9, 2021.
  • Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers.
  • Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Pops AI Virtual Health Assistant and Glucometer Now Available at Best Buy

Monday, July 26, 2021 - 7:44pm

Popsa transformational virtual diabetes management companyand Best Buy have reached agreement on a distribution collaboration enabling more people with diabetes to utilize the Pops solution.

Key Points: 
  • Popsa transformational virtual diabetes management companyand Best Buy have reached agreement on a distribution collaboration enabling more people with diabetes to utilize the Pops solution.
  • The electronics retailer offers customers a variety of products within the health and wellness space including fitness and recovery, pain management, personal care, health monitoring and more.
  • Pops provides a consumer-centric solution to enable people to manage their condition while they live their life.
  • The solution centers around Mina, an AI virtual health assistant, who is with the person 24/7 in their phone.

Senseonics Holdings, Inc. Schedules Second Quarter 2021 Earnings Release and Conference Call for August 9, 2021, at 4:30 p.m. Eastern Time

Monday, July 26, 2021 - 9:05pm

Management will hold a conference call to review the companys second quarter 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day.

Key Points: 
  • Management will hold a conference call to review the companys second quarter 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day.
  • To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 4998185, approximately ten to five minutes prior to start time.
  • Senseonics' CGM Systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.
  • The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Global Urolithiasis Management Devices Industry (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com

Monday, July 26, 2021 - 5:45pm

The "Urolithiasis Management Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Urolithiasis Management Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Urolithiasis Management Devices estimated at US$1.5 Billion in the year 2020, is projected to reach a revised size of US$2.1 Billion by 2027, growing at a CAGR of 4.6% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $416.7 Million, While China is Forecast to Grow at 7.4% CAGR
    The Urolithiasis Management Devices market in the U.S. is estimated at US$416.7 Million in the year 2020.
  • In the global Percutaneous Nephrolithotomy segment, USA, Canada, Japan, China and Europe will drive the 4.4% CAGR estimated for this segment.

Latin America In-Vitro Diagnostic Tests Research Report 2021 - ResearchAndMarkets.com

Monday, July 26, 2021 - 5:09pm

The "The Market for In Vitro Diagnostic Tests in Latin America" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Market for In Vitro Diagnostic Tests in Latin America" report has been added to ResearchAndMarkets.com's offering.
  • Latin America (LATAM) is a key target for IVD manufacturers exploring expansion opportunities.
  • This report, The Market for In Vitro Diagnostic Tests in Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela and other nations), focuses on the market for reagents and instruments in the most important countries of the continent.
  • Immunoassay (non-microbiology): hormones, tumor markers, bone markers, oncology markers, autoimmunity, allergy, anemia, neonatal tests, prenatal tests, interleukins, PCT.